logo banner home news contact
nav

news

events

 

News

Return to News

Argos Therapeutics Presents Data on the Mechanism of Immunosuppression by Soluble CD83 at the Canadian Society of Transplantation Congress


Durham, NC- February 28, 2008 - Argos Therapeutics today announced the presentation of data on the immunosuppressive properties of its soluble CD83 (sCD83) protein at the 2008 Annual Scientific Meeting of the Canadian Society of Transplantation, held February 28 - March 2 in Mont-Tremblant, Quebec. The presentation, which will be made on February 29 by Argos´ collaborating scientists at the University of Western Ontario, will review data demonstrating that sCD83-treated dendritic cells from non-human primates are able to induce regulatory T cells in vitro.

“The ability of sCD83-treated dendritic cells to induce regulatory T cells, which are responsible for suppressing the immune system response and maintaining tolerance to self-antigens, validates Argos´ program for evaluating sCD83´s utility in treating transplantation rejection and a number of autoimmune disorders,” commented Charles Nicolette, Ph.D., Chief Scientific Officer at Argos. “The ability of sCD83 to induce regulatory T cells directly on pre-activated T cells, or indirectly through the induction of tolerogenic dendritic cells, offers valuable insight into the mechanism of action of sCD83, and provides further impetus to move this exciting protein into a clinical setting following preclinical studies demonstrating its promising activity as an efficient immunosuppressant.”

The presented abstract is titled, “The Soluble Extracellular Domain of CD83 as a Novel Agent for the In vitro Generation of Regulatory T cells in Cynomolgus Monkeys,” and was authored by Miren L. Baroja, Ph.D.; Jacqueline Arp, Ph.D.; Siobhan I. Ramcharan, B.Sc.; Stephen Brand, Ph.D.; Anthony M. Jevnikar, M.D., M.Sc.; Gill Strejan, Ph.D.; William Wall, M.D.; and Hao Wang, M.D., M.Sc.

About Soluble CD83
CD83 is a glycoprotein expressed on the cell surface of mature dendritic cells (DCs), the most potent stimulators of immune responses. The strong up-regulation of this protein during DC maturation suggests that it plays an important functional role in the induction of immune responses. Experimental data demonstrate that soluble CD83 can potently down-regulate immune responses, indicating that it can be developed to treat transplantation rejection and variety of autoimmune disorders. Importantly, data from animal models demonstrate that soluble CD83 exerts its effects without a requirement for chronic administration and does not leave the subject globally immunosuppressed.


About Argos Therapeutics, Inc.
Argos Therapeutics is developing breakthrough immunotherapies that target the unique features of a patient´s disease. This new generation of personalized cancer and infectious disease therapeutics, created using the Company´s “Arcelis” technology, trains the immune system to recognize and attack the disease. Argos´ scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases. www.argostherapeutics.com

Argos is a private biotechnology company headquartered in Research Triangle Park, NC. The Company has clinical trial programs in cancer and human immunodeficiency virus (HIV) and has an ongoing co-development and commercialization alliance with the Kirin Pharma Company, Ltd.

Contacts:
Jennifer Greenleaf
MacDougall Biomedical Communications
(781) 235-3060

Jeff Abbey
Argos Therapeutics
(919) 287-6308

print friendly version

# # #